Abstract
Background: A lot of recent researches have focused on the duration of the nature immunity elicited by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. An improved understanding of the immunity offered by the antibodies developed against SARS-CoV-2 in recovered patients is critical for the development of diagnostic tests and vaccines. Methods: We enrolled 114 donors, which providing blood samples after discharge for half a year and one year. Neutralizing antibodies (NAbs) were tested using a micro-neutralization assay. Results: In two tests, 82 of 114 recovered patients completed the first test half a year after discharge and NAbs remained detectable in the vast majority of patients (75/82, 91.46%). In the comparison of the two intervals, 50% (27/54) of individuals had increased NAbs titers. when 31.48% (17/54) of patients remained unchanged. Conclusion: Our results suggest that immune ability is acquired in most individuals infected with SARS-CoV-2 and is sustained in a majority of patients for up to a year after recovery.
Introduction
Understanding the durability of natural immunity following SARS-CoV-2 infection is vital for shaping public health strategies and vaccination schedules. While early research focused on short-term responses, this longitudinal study tracks 114 COVID-19 survivors over a full year to determine the long-term kinetics of neutralizing antibodies (NAbs)—the "gold standard" of immune protection.
Methods
The study followed 114 patients across three hospitals in China, collecting blood samples at six months and one year post-discharge.
- Micro-neutralization Assay: Researchers used a whole-virus replication assay (strain No.20SF014) to measure the ability of patient serum to prevent viral cytopathic effects in cell culture.
- Quantification: Results were recorded as Geometric Mean Titers (GMT), defined as the highest serum dilution protecting >50% of cells.
- Statistical Analysis: Differences based on age, gender, and clinical severity were evaluated using Chi-square, Kruskal-Wallis, and Mann-Whitney U tests.
Results and Patient Characteristics
The study cohort (median age ~37.6 years, 50.88% female) included a range of clinical severities, from asymptomatic to moderate cases.
Long-term Antibody Persistence
At the six-month mark, 91.46% (75/82) of patients remained seropositive with a GMT of 1:23.21. By the one-year mark, while the average GMT dipped slightly to 1:17.09, the majority of patients maintained detectable protection, indicating a stable plateau of humoral immunity.
Comparative Dynamics: The "U-Turn" Effect
In a subset of 54 patients with complete longitudinal data, researchers observed a surprising trend: antibody levels did not universally decay. Instead, 50% (27/54) of individuals showed an increase in NAb titers between the six-month and one-year intervals.
Statistical analysis revealed that clinical severity was a primary predictor of these dynamics (p = 0.003). Patients with moderate symptoms developed higher and more durable antibody levels than those with mild or asymptomatic infections. Additionally, older patients and those with longer initial disease progression were more likely to fall into the "increased" or "stable" antibody groups.
Discussion and Limitations
The findings suggest that the immune system's memory may continue to mature or reactivate long after recovery. However, several limitations exist:
- Sample Size: Only 54 patients provided samples for both time points.
- Scope: The study focused on humoral immunity (antibodies) and did not assess cellular immunity (T-cells).
- Variants: The research utilized an early 2020 strain; the efficacy of these antibodies against later variants like Delta or Omicron remains unknown.
Conclusion
Natural immunity to SARS-CoV-2 is robust and sustained for at least one year in most individuals. The observation of increasing titers in half of the longitudinal cohort suggests a complex, long-term immune maturation process that warrants further investigation.
Summary updated